Jean-Pierre Routy Selected Research

HIV Infections (HIV Infection)

1/2022	Th17 CD4+ T-Cell as a Preferential Target for HIV Reservoirs.
11/2021	Evolution of Antibodies to Native Trimeric Envelope and Their Fc-Dependent Functions in Untreated and Treated Primary HIV Infection.
11/2021	IL-17A reprograms intestinal epithelial cells to facilitate HIV-1 replication and outgrowth in CD4+ T cells.
9/2021	Dynamics and epigenetic signature of regulatory T-cells following antiretroviral therapy initiation in acute HIV infection.
4/2021	Diurnal Variation of Plasma Extracellular Vesicle Is Disrupted in People Living with HIV.
1/2021	RALDH Activity Induced by Bacterial/Fungal Pathogens in CD16+ Monocyte-Derived Dendritic Cells Boosts HIV Infection and Outgrowth in CD4+ T Cells.
12/2020	Cytomegalovirus Seropositivity Is Associated With Increased Microbial Translocation in People Living With Human Immunodeficiency Virus and Uninfected Controls.
12/2020	Impact of extended-release niacin on immune activation in HIV-infected immunological non-responders on effective antiretroviral therapy.
4/2020	Persistent expansion and Th1-like skewing of HIV-specific circulating T follicular helper cells during antiretroviral therapy.
1/2020	Circulating (1→3)-β-D-glucan Is Associated With Immune Activation During Human Immunodeficiency Virus Infection.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jean-Pierre Routy Research Topics

Disease

68	Infections 01/2022 - 02/2002
61	HIV Infections (HIV Infection) 01/2022 - 08/2002
31	Acquired Immunodeficiency Syndrome (AIDS) 01/2022 - 11/2002
27	Inflammation (Inflammations) 01/2022 - 01/2014
20	Disease Progression 12/2020 - 04/2007
14	Neoplasms (Cancer) 01/2022 - 12/2009
13	Virus Diseases (Viral Diseases) 01/2022 - 01/2010
8	Persistent Infection 01/2022 - 03/2002
6	COVID-19 01/2022 - 01/2020
6	Viremia 01/2021 - 02/2002
4	Cardiovascular Diseases (Cardiovascular Disease) 06/2021 - 01/2017
4	Kaposi Sarcoma (Kaposi's Sarcoma) 01/2021 - 11/2002
3	Atherosclerosis 10/2021 - 06/2020
2	Cytokine Release Syndrome 01/2022 - 01/2017
2	Pneumonia (Pneumonitis) 10/2021 - 09/2009
2	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 10/2021 - 01/2020
2	Ulcerative Colitis 03/2021 - 01/2021
2	Pancytopenia 01/2021 - 01/2021
2	Sexually Transmitted Diseases (Sexually Transmitted Disease) 01/2021 - 07/2018
2	Dysbiosis 10/2020 - 04/2016
2	Weight Loss (Weight Reduction) 09/2020 - 01/2020
2	Non-alcoholic Fatty Liver Disease 01/2020 - 11/2016
2	Hepatitis 10/2018 - 07/2018
2	Breast Neoplasms (Breast Cancer) 12/2017 - 01/2016
2	Liver Cirrhosis (Hepatic Cirrhosis) 11/2016 - 03/2016
2	Multi-centric Castleman's Disease 06/2008 - 11/2002
2	Human Influenza (Influenza) 11/2005 - 11/2005
1	Hypoxia (Hypoxemia) 01/2022

Drug/Important Bio-Agent (IBA)

22	CytokinesIBA 01/2022 - 11/2005
14	Biomarkers (Surrogate Marker)IBA 01/2022 - 09/2008
10	DNA (Deoxyribonucleic Acid)IBA 03/2021 - 11/2002
10	VaccinesIBA 01/2021 - 07/2007
10	Pharmaceutical PreparationsIBA 03/2019 - 08/2002
9	KynurenineIBA 01/2021 - 01/2015
9	Tryptophan (L-Tryptophan)FDA Link 01/2021 - 10/2014
8	Antiviral Agents (Antivirals)IBA 01/2022 - 11/2005
8	Interleukin-18 (Interleukin 18)IBA 01/2021 - 06/2009
7	Peptides (Polypeptides)IBA 01/2016 - 03/2002
6	Proteins (Proteins, Gene)FDA Link 01/2018 - 05/2005
6	Protease Inhibitors (Protease Inhibitor)IBA 11/2016 - 02/2002
5	RNA (Ribonucleic Acid)IBA 03/2021 - 01/2012
5	Metformin (Glucophage)FDA LinkGeneric 03/2021 - 01/2019
5	AntigensIBA 01/2021 - 02/2002
5	Interleukin-2 (IL2)IBA 01/2016 - 05/2009
5	EnzymesIBA 01/2016 - 08/2011
5	HLA-B57 antigenIBA 01/2014 - 07/2007
4	interleukin-21 (interleukin 21)IBA 01/2022 - 09/2008
4	ChemokinesIBA 11/2021 - 12/2015
4	Protein Isoforms (Isoforms)IBA 10/2021 - 12/2019
4	Rituximab (Mabthera)FDA Link 01/2021 - 06/2008
4	Interleukin-7 (Interleukin 7)IBA 01/2017 - 01/2012
4	LigandsIBA 10/2016 - 11/2010
4	HLA-B Antigens (HLA-B)IBA 10/2016 - 07/2008
3	Growth Differentiation Factor 15IBA 01/2022 - 01/2020
3	Interleukin-17 (Interleukin 17)IBA 11/2021 - 01/2020
3	LipopolysaccharidesIBA 06/2021 - 01/2020
3	MicroRNAs (MicroRNA)IBA 04/2021 - 11/2015
3	Biological ProductsIBA 01/2021 - 03/2010
3	Glucose (Dextrose)FDA LinkGeneric 10/2020 - 01/2018
3	Hypoglycemic Agents (Hypoglycemics)IBA 10/2020 - 01/2019
3	Interleukin-33IBA 01/2017 - 01/2016
3	Interferon-gamma (Interferon, gamma)IBA 11/2014 - 03/2002
3	KIR ReceptorsIBA 01/2014 - 03/2008
3	Reverse Transcriptase InhibitorsIBA 03/2009 - 03/2005
3	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 12/2004 - 02/2002
2	Immunoglobulin G (IgG)IBA 11/2021 - 12/2020
2	AntibodiesIBA 11/2021 - 01/2018
2	InterleukinsIBA 10/2021 - 12/2003
2	Interleukin-12 (IL 12)IBA 01/2021 - 06/2009
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2021 - 01/2013
2	Indoleamine-Pyrrole 2,3,-Dioxygenase (Indoleamine 2,3 Dioxygenase)IBA 01/2021 - 01/2016
2	AIDS VaccinesIBA 01/2020 - 09/2017
2	Human Immunodeficiency Virus ProteinsIBA 01/2019 - 01/2007
2	TNF Receptor-Associated Factor 1IBA 01/2018 - 01/2012
2	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 12/2017 - 01/2016
2	Messenger RNA (mRNA)IBA 01/2017 - 01/2016
2	AlarminsIBA 01/2017 - 01/2016
2	Natural Killer Cell ReceptorsIBA 10/2016 - 07/2008
2	Lipopolysaccharide ReceptorsIBA 03/2016 - 01/2014
2	EpitopesIBA 11/2014 - 11/2005
2	Broadly Neutralizing AntibodiesIBA 05/2013 - 06/2011
2	Tretinoin (Retinoic Acid)FDA LinkGeneric 01/2012 - 04/2011
2	IntegrinsIBA 01/2012 - 04/2011
2	NucleosidesIBA 04/2008 - 03/2005
2	Peptide Hydrolases (Proteases)FDA Link 04/2008 - 09/2004
2	Amino Acids FDA Link 07/2007 - 03/2004
2	Ritonavir (Norvir)FDA Link 03/2005 - 03/2004
2	Lamivudine (Epivir)FDA Link 03/2005 - 12/2004
1	Immune Checkpoint InhibitorsIBA 01/2022
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2022
1	HIV ReceptorsIBA 01/2022
1	CCR6 ReceptorsIBA 01/2022
1	CD4 Antigens (CD4 Antigen)IBA 01/2022
1	trans-crotonin (CTN)IBA 12/2021

Therapy/Procedure

33	Therapeutics 01/2022 - 02/2002
23	Art Therapy 01/2022 - 08/2015
13	Immunotherapy 01/2021 - 12/2009
6	Highly Active Antiretroviral Therapy (HAART) 01/2016 - 03/2003
4	Drug Therapy (Chemotherapy) 01/2022 - 03/2003
1	Long-Term Care 01/2022